Zevra Therapeutics, Inc. GAAP EPS of $0.19 beats by $0.14, revenue of $34.1M beats by $6.05M
Source: SeekingAlpha
2026-03-09 16:08:09 ET
More on Zevra Therapeutics, Inc.
- Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market
- Zevra Therapeutics, Inc. Q4 2025 Earnings Preview
- Zevra Therapeutics appoints Justin Renz as CFO
Read the full article on Seeking Alpha
For further details see:
Zevra Therapeutics, Inc. GAAP EPS of $0.19 beats by $0.14, revenue of $34.1M beats by $6.05M
Zevra Therapeutics Inc.
NASDAQ: ZVRA
ZVRA Trading
18.74% G/L:
$10.805 Last:
6,526,153 Volume:
$10.95 Open:
ZVRA Latest News
ZVRA Stock Data
$484,721,776
54,946,394
0.39%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Celebration
